Trial Profile
Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2019
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms HepNet Acute HCV IV
- 15 Jul 2016 Status changed from active, no longer recruiting to completed.
- 06 Apr 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2016, according to ClinicalTrials.gov record.
- 06 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.